They showed that there was a statistically significant difference in the ratio of CD8 T-cells to FOXP3 T-regulatory cells (CD8/FOXP3) detected in tumor cells following SBRT as compared to conventionally fractionated therapy. Here, CD8A is linked to neoplasm.